Successful exit just 1.5 years after the Company’s founding proves investment rationale
EMBL Ventures portfolio company Luxendo acquired by Bruker
Arsanis Completes $45.5 Million Series D Financing
Company set to advance pipeline of monoclonal antibodies for serious infectious diseases, including lead Phase 2 program ASN100 for the prevention of Staphylococcus aureus pneumonia in high-risk ICU patients
Paul Sekhri joins Topas Therapeutics as Chairman of the Board
Topas Therapeutics GmbH (Topas), a privately held biotech company pursuing a novel liver-based immune tolerance approach, today announced the election of Paul Sekhri as Chairman of the Board effective immediately.